U.S. stocks edge higher; solid earnings season continues
CytoSorbents Corporation (NASDAQ:CTSO), a medical device company with a market capitalization of $68.56 million and revenue growth of 15.37% in the last twelve months, reported the outcomes of its 2025 Annual Meeting of Stockholders on June 12, 2025. According to InvestingPro analysis, the company maintains a FAIR financial health rating despite currently operating at a loss. The meeting’s agenda included the election of directors, executive compensation approval, and ratification of the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. While the company faces profitability challenges, InvestingPro data shows it maintains strong liquidity with a current ratio of 2.61, indicating solid short-term financial stability.
A quorum was achieved at the meeting with 40,071,481 shares represented, out of the 62,610,376 shares outstanding as of the April 17, 2025 record date. The company’s stockholders elected five directors to serve until the 2026 Annual Meeting or until their successors are elected. Additionally, the stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers as disclosed under SEC regulations.
Furthermore, the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified by the stockholders.
The detailed voting results for each proposal are as follows:
1. Election of Directors:
- Dr. Phillip P. Chan received 21,479,032 votes for, 1,107,546 against, and 64,976 abstentions.
- Dr. Edward R. Jones received 19,790,544 votes for, 2,791,100 against, and 69,910 abstentions.
- Michael Bator received 19,687,559 votes for, 2,705,796 against, and 258,199 abstentions.
- Alan D. Sobel received 19,313,170 votes for, 3,319,370 against, and 19,014 abstentions.
- Jiny Kim received 21,388,189 votes for, 913,647 against, and 349,718 abstentions.
- Each nominee had 17,419,927 broker non-votes.
2. Approval of the Compensation of the Company’s Named Executive Officers:
- 18,189,951 votes for, 1,720,512 against, 2,741,091 abstentions, and 17,419,927 broker non-votes.
3. Ratification of the Appointment of Independent (LON:IOG) Registered Public Accounting Firm:
- 39,485,868 votes for, 553,680 against, and 31,933 abstentions.
The results of the annual meeting reflect the shareholders’ support for the company’s governance and executive compensation practices. The information presented in this article is based on the company’s SEC filing. The stock has shown resilience with a 26% price return over the past year, though investors should note that analysts don’t expect profitability in the current fiscal year. For deeper insights into CTSO’s financial health and growth prospects, including additional ProTips and comprehensive analysis, check out the detailed Pro Research Report available on InvestingPro.
In other recent news, CytoSorbents Corporation reported its first-quarter 2025 financial results, revealing a larger-than-expected loss in earnings per share (EPS) and a revenue shortfall. The company’s EPS was -$0.06, missing the forecast of -$0.05, while revenue fell to $8.7 million, below the expected $10.82 million. Despite these financial challenges, CytoSorbents announced promising clinical findings at the EuroPCR 2025 conference. The use of their CytoSorb® device during coronary artery bypass grafting (CABG) surgery was shown to significantly reduce severe bleeding complications in patients. Additionally, CytoSorbents disclosed that its Series B Right Warrants expired without value due to stock price shortfall, and funds received for the exercise of these warrants will be returned to investors. The company is also awaiting regulatory decisions for its DrugSorb-ATR system in the United States and Canada, with hopes of a market introduction later this year. Meanwhile, CytoSorbents is focusing on strategic initiatives, including a new subsidiary in Dubai and efforts to reignite growth in the German market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.